IMMEDIATE.
ACCURATE.
ANYWHERE.
First and only automated sperm morphology and ovulation detection device using Artificial Intelligence
FERTILE-EYEZ is the technology that can bring semen and ovulation assessments into the 21st Century and become the industry standard that provides IMMEDIATE, ACCURATE results ANYWHERE you need it!
TM
WELCOME TO THE FUTURE OF ANIMAL BREEDING
FERTILE-EYEZ is a Mobile Sperm Analysis & Ovulation Detection Device that rapidly provides a snapshot of fertility using patent-pending image recognition and artificial intelligence (AI) technology from Brigham & Women’s Hospital. It is the first true AI fertility device in the animal health industry. It is highly accurate and correlated with current gold standards.
IT IS LIKE HAVING A SKILLED LAB TECHNICIAN AND A MICROSCOPE IN THE PALM OF YOUR HAND
This tool removes all subjectivity of sperm analysis & ovulation detection since the person reading the sample is completely removed and it no longer requires someone to send samples to a lab or a different part of the farm for analysis.
CONCEPTION RATE IS HIGHLY CORRELATED WITH PRODUCER PROFITABILITY
This new mobile fertility platform will change how testing is done in the breeding sheds across several major species resulting in increased performance of livestock production facilities and furthering superior genetics. This will allow industry players access to mobile product fertility attributes never before seen at such an affordable rate. Veterinarians, Producers, and Breeders from across the world will finally have line-of-sight and access to cell morphology fertility parameters as they seek improvements in their animal production systems.
THIS AMAZING TECHNOLOGY HAS BEEN PROVEN IN BOTH HUMANS AND BOARS
Fertile-Eyez was originally developed for humans to improve the user experience by allowing sample testing at home versus in-clinic and was recently proven in boars at Purdue University.
TM
TM
PUBLICATION & NEWS COVERAGE
As Featured In:
Watch Liane Hart, our CEO & Co-Founder, speak at the Women in Entrepreneurship Panel Hosted by Purdue University on April 14, 2022 in the Purdue Memorial Union
INVITED PRESENTATIONS
Chosen to present at the KC Animal Health Investment Forum Pitch Competition in 2018.
Event is for early stage entrepreneurs in the animal health and nutrition industry to present their vision and business plan to an audience of venture capitalists, investment firms, and animal health. Held in Kansas City.
Chosen to present pitch video at the THRIVE Accelerator Program VI in 2019.
They support seed stage startups from all areas of the value chain whose technologies drive us towards a more efficient, sustainable, and secure the future of agriculture.
Chosen to present at the Elevate Central Regional Pitch Competition in 2019.
They offer promising startups, preferably engaged with Elevate Nexus partnered colleges and universities, the opportunity to secure foundational capital needed to launch their businesses. Partnered with Purdue Foundry.
Global Reach
There are strong global patent filings and license barriers to this technology as well as data aggregation and ownership protections.
The FERTILE-EYEZ technology is originally from Brigham and Women’s Hospital. Verility, LLC has the exclusive right to negotiate a worldwide, royalty-bearing license to patent rights in the field of semen analysis for veterinary use.
TM
“A lot can go wrong between the breeder and point of insemination. So, checking [the sample] at the farm prior to use would be a benefit.”
“The cost of missing a cycle is high. Especially in dairy and swine. Helping to reduce that cost is a big benefit.”
“There is a trend toward measuring everything at the farm level. A tremendous amount of data is being collected and analyzed. But [semen quality] seems to be overlooked, probably because the producer hasn’t had a way to evaluate it. Now they could and it is time to put some focus on it with everything else.”
“Taking the subjectivity out of the analysis seems to be a big benefit. Especially if there is a way to provide a definite go / no-go recommendation.”